Our Science – Sissung Website
Tristan Sissung, Ph.D., M.S.
Selected Publications |
 |
| 1)
Sissung TM, Reece KM, Spencer S, Figg WD. Contribution of the OATP1B subfamily to cancer biology and treatment. Clin. Pharmacol. Ther. 92: 658-60, 2012. [Journal] |
|
| 2)
Pratt E, Sissung TM, Figg WD. Loss of OATP1B3 function causes Rotor syndrome: Implications for potential use of inhibitors in cancer. Cancer Biol. Ther. 13, 2012. [Journal] |
|
| 3)
Troutman SM, Sissung TM, Cropp CD, Venzon DJ, Spencer SD, Adesunloye BA, Huang X, Karzai FH, Price DK, Figg WD. Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis. Oncologist. 17: 312-20, 2012. [Journal] |
|
| 4)
Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel J, Venzon D, Dahut W, Kohn E, Kummar S, Yarchoan R, Giaccone G, Widemann B, Figg WD. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin. Cancer Res. 18: 2099-107, 2012. [Journal] |
|
| 5)
Sissung TM, Troutman SM, Campbell TJ, Pressler HM, Sung H, Bates SE, Figg WD. Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy. Discov Med. 13: 19-34, 2012. [Journal] |
|
| 6)
Peer CJ, Sissung TM, Figg WD. CHIP and gp78-mediated ubiquitination of CYP3A4: Implications for the pharmacology of anticancer agents. Cancer Biol. Ther. 11: 549-51, 2011. [Journal] |
|
| 7)
Sissung TM, Danesi R, Kirkland CT, Baum CE, Ockers SB, Stein EV, Venzon D, Price DK, Figg WD. Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. J. Clin. Endocrinol. Metab. 96: E368-72, 2011. [Journal] |
|
| 8)
Pressler H, Sissung TM, Venzon D, Price DK, Figg WD. Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS ONE. 6: e20372, 2011. [Journal] |
|
| 9)
Sissung TM, Gardner ER, Piekarz RL, Howden R, Chen X, Woo S, Franke R, Clark JA, Miller-DeGraff L, Steinberg SM, Venzon D, Liewehr D, Kleeberger SR, Bates SE, Price DK, Rosing DR, Cabell C, Sparreboom A, Figg WD. Impact of ABCB1 allelic variants on QTc interval prolongation. Clin. Cancer Res. 17: 937-46, 2011. [Journal] |
|
| 10)
Sissung TM, Pressler H, Price DK, Figg WD. SLCO transport genes in prostate cancer--letter. Cancer Epidemiol. Biomarkers Prev. 20: 2325; author reply 2326-7, 2011. [Journal] |
|
| Click Here to View Expanded Bibliography. |
This page was last updated on 12/21/2012.
